Biomea Fusion Inc BMEA announced the poster presentation of long-term 26 weeks follow-up data from the first two cohorts of adults with type 2 diabetes (T2D) enrolled in the ongoing Phase 2 study (COVALENT-111) and data from preclinical ex-vivo human islet experiments of BMF-219.
At Week 26, 22 weeks after the last dose of BMF-219, participants in the 100 mg BMF-219 QD (without food) cohort saw an improved placebo-adjusted mean reduction in HbA1c of 0.8%.
Participants in the 100 mg BMF-219 QD (with food) cohort saw an improved placebo-adjusted mean reduction in HbA1c of 0.2% at Week 26
20% of patients from the 100mg dose cohorts displayed a reduction in HbA1c of 1% or more, compared to 0% of patients for placebo at Week 26
After only four weeks of dosing and 22 weeks off treatment, participants in BMF-219 100 mg QD without food cohort demonstrated an 80% response rate – with any reduction in HbA1c (40% response rate in 100 mg QD with food cohort).
The company also shared preclinical ex-vivo human islet data for BMF-219.
Dependent on dose concentration and dose duration, BMF-219 was observed to increase beta cell mass and function, promote controlled proliferation, and enhance insulin content in beta cells.
Price Action: BMEA shares are down 17.90% at $12.35 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
